Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Vigil Engineered Autologous Tumor Cell Immunotherapy in Subjects With Stage IIIb-IV Ovarian Cancer in Clinical Complete Response Following Surgery and Primary Chemotherapy

NCT02346747 is registered in ClinicalTrials.gov with Gradalis, Inc. as lead sponsor.

NCT NCT02346747
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02346747 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Vigil Engineered Autologous Tumor Cell Immunotherapy in Subjects With Stage IIIb-IV Ovarian Cancer in Clinical Complete Response Following Surgery and Primary Chemotherapy
Lead sponsor
Gradalis, Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
February 28, 2015
Completion date
December 31, 2028
Enrollment
92 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer, ovarian neoplasms